Your search for topamax returned 36 results

Active Filters

Click on a filter below to refine your search. Remove a filter to broaden your search.

Your search for topamax returned 36 results

Sort Results:

Relevant Recent
Drug Monograph

FOSAMAX

Alendronate (as sodium) 70mg; tabs.
Drug Monograph

FOSAMAX PLUS D

Alendronate (as sodium), cholecalciferol (Vit. D3); 70mg/2800 IU, 70mg/5600 IU; tabs.
News

First Adolescent Migraine Prophylactic Approved

The FDA has approved Topamax (topiramate; Janssen) for migraine prophylaxis in adolescents aged 12-17 years old. This is the first drug approval for a migraine prophylactic in this age group.
News

New appearance for Topamax tablets

Ortho-McNeil Neurologics has announced that it is changing the appearance of Topamax (topiramate) Tablets to help reduce medication errors involving Toprol XL (metoprolol succinate extended-release tablets, from AstraZeneca).
Uncategorized

RECALL: Two Lots of Topamax Recalled

Ortho-McNeil Neurologics announced a voluntary recall of two lots of Topamax (topiramate) 100mg tablets, 60-count bottles, because of an uncharacteristic odor thought to be caused by trace amounts of TBA (2,4,6 tribromoanisole).
Drugs in the Pipeline

Topiramate Injection Receives Orphan Drug Status

The FDA has granted Captisol-enabled Topiramate Injection (Ligand Pharmaceuticals) Orphan Drug Designation for the treatment of partial onset or primary generalized tonic-clonic seizures in hospitalized epilepsy patients who are unable to take oral topiramate.
Drug Monograph Updates

May 2014 Recap of Drug Updates

The summary below gives an overview of important additions and changes MPR has made to its drug database through the end of May. The chart below provides highlights of key monograph updates made this month (not an inclusive list).
Uncategorized

FDA Warns of Cleft Lip or Palate in Newborns with Topiramate

The FDA notified healthcare professionals and patients that topiramate (Topamax; Ortho-McNeil) is now being placed in Pregnancy Category D after new human data showed an increased risk of development of cleft lip and/or cleft palate in infants born to women treated with topiramate during pregnancy.